Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of ...
The Mobile City Council approved a proposal to apply for a $400,000 federal grant to help fund the next phase of the Greenway ...
Fidelix Co., Ltd ( ($KR:032580) ) just unveiled an announcement. Fidelix Co., Ltd. reported its third-quarter 2026 status with stable capital, an unchanged share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results